Skip to content
Open menu

Thyroid cancer

Thyroid cancer has increased in recent years. It is known to be more common in women than in men. On average, thyroid cancer is diagnosed in patients 25 to 65 years of age.

It is reassuring to know that thyroid cancer is treatable in most cases. Thyroid cancer has one of the highest five-year survival rates of all cancers. This means that thyroid cancer patients have a very good chance of being cancer-free five years from the diagnosis.

There are three types of thyroid cancers: papillary, follicular and medullary thyroid cancer. They are distinguished from each other on the basis of the microscopic cytological picture, and they behave differently. Papillary thyroid cancer is the most common type of thyroid cancer and, fortunately, also the least malignant. Follicular thyroid cancer is the second most common, and the medullary type is the least common.

Risk of disease

In most cases, the cause of thyroid cancer cannot be identified. The only known risk factor for thyroid cancer is exposure to ionising radiation, such as radiotherapy administered to the neck area years ago or exposure to a nuclear disaster. Such causes are extremely rare. Treatment of hyperthyroidism with radioiodine does not increase the risk of cancer. After the emission of radioactive iodine into the air during the Chernobyl nuclear plant disaster, a significant increase in the occurrence of thyroid cancer was detected in nearby regions.

Symptoms

The most common and often only symptom of thyroid cancer is a lump in the neck, growing quite slowly over months. Such a palpable lump detected in the neck must always be examined. Thyroid cancer may also cause swelling of lymph nodes in the neck. If the cancer has spread into the structures of the neck, this may cause hoarseness or difficulty swallowing. However, these can also be general symptoms of other diseases.

Diagnosis

A lump in the thyroid gland can be examined by ultrasound scans and thin-needle biopsies. An ultrasound scan does not tell whether a tumor is malignant or benign, but it may give some information about its nature and helps to target a thin sampling needle accurately to the tumor. The cells remaining in the needle are analysed under a microscope. This can only be done by a pathologist.

A thin-needle biopsy is usually a reliable method for detecting papillary and medullary thyroid cancers, whereas the diagnosis of follicular cancer usually requires an additional, larger biopsy specimen of the thyroid gland. Often the lobe of the thyroid gland in which the tumor resided is removed at the same time.

The most reliable way of determining the nature of a lump is to remove it. This is recommended if the lump is large, exceptionally hard and rapidly grown, or if the patient has previously received radiotherapy to the neck area. Lab tests are usually not useful for the diagnosis of thyroid cancer.

Treatment

Treatments for thyroid cancer include surgery, radioiodine therapy, external radiotherapy and chemotherapy. Surgery is the basic treatment for thyroid cancer. The objective is to remove the entire thyroid gland as thoroughly as possible. Possibly affected nearby lymph nodes are removed at the same time. In papillary and follicular cancers, radioiodine therapy is administered postoperatively. Patients operated on will need a thyroxine supplement for the rest of their life; after the removal of the thyroid gland, the body no longer produces this hormone.

Read more

Breast reconstruction surgery means meticulous craftsmanship by experienced surgeons

Reconstructing a removed breast is part of the treatment path of many breast cancer patients. The goal of the surgery...

Read more

Chief Clinical Director of Docrates Cancer Center: “Genetic information is an essential part of modern cancer care”

New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...

Customer message 3. September, 2024

With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...

The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center

On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00